These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 17642245)
1. [Effective combination therapy of TNF antagonists with DMARDs]. Ohtsubo H; Matsuda T Nihon Rinsho; 2007 Jul; 65(7):1287-91. PubMed ID: 17642245 [TBL] [Abstract][Full Text] [Related]
2. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients. Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Benucci M; Saviola G; Baiardi P; Manfredi M; Sarzi-Puttini P; Atzeni F Int J Immunopathol Pharmacol; 2011; 24(1):269-74. PubMed ID: 21496415 [TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Wisłowska M; Jakubicz D Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556 [TBL] [Abstract][Full Text] [Related]
5. [New drugs and treatment strategies for rheumatoid arthritis]. Fantini F Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798 [TBL] [Abstract][Full Text] [Related]
6. [TNF inhibitors for treatment of rheumatoid arthritis]. Otomo K; Koike T Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036 [No Abstract] [Full Text] [Related]
7. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. Doan QV; Chiou CF; Dubois RW J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801 [TBL] [Abstract][Full Text] [Related]
8. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Finckh A; Simard JF; Duryea J; Liang MH; Huang J; Daneel S; Forster A; Gabay C; Guerne PA Arthritis Rheum; 2006 Jan; 54(1):54-9. PubMed ID: 16385495 [TBL] [Abstract][Full Text] [Related]
9. [Selection of one of the TNF blockers; infliximab and etanercept]. Mimura T Nihon Rinsho; 2007 Jul; 65(7):1282-6. PubMed ID: 17642244 [TBL] [Abstract][Full Text] [Related]
10. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912 [TBL] [Abstract][Full Text] [Related]
11. [When to begin rheumatism treatment? Initial combination therapy helps fastest]. Fath R MMW Fortschr Med; 2004 Sep; 146(37):5-6. PubMed ID: 15887691 [No Abstract] [Full Text] [Related]
12. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289 [TBL] [Abstract][Full Text] [Related]
13. [Biologic therapy with anti-TNFα in rheumathoid arthritis]. Ferraccioli G Reumatismo; 2005; 57(4 Suppl):17-21. PubMed ID: 16385351 [TBL] [Abstract][Full Text] [Related]
14. [Proper usage of biologics for treatment of rheumatoid arthritis]. Murayama M Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):894-8. PubMed ID: 19469085 [No Abstract] [Full Text] [Related]
15. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Lee YH; Woo JH; Rho YH; Choi SJ; Ji JD; Song GG Rheumatol Int; 2008 Apr; 28(6):553-9. PubMed ID: 17943257 [TBL] [Abstract][Full Text] [Related]
17. [Biologicals in the treatment of rheumatic diseases]. Scherer HU; Burmester GR Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270 [No Abstract] [Full Text] [Related]
18. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Kristensen LE; Saxne T; Nilsson JA; Geborek P Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678 [TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Bonafede MM; Gandra SR; Fox KM; Wilson KL J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705 [TBL] [Abstract][Full Text] [Related]
20. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response. Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]